Albany Molecular Research (AMRI) Tops Q2 EPS by 4c; Guides Q3 Contract Revs
Tweet Send to a FriendGet Alerts AMRI Hot Sheet
Price: $11.78 -1.59%
Revenue Growth %: +10.6%
Financial Fact:
Impairment charges: 534K
Today's EPS Names:
ATU, CRWS, CLC, More
Revenue Growth %: +10.6%
Financial Fact:
Impairment charges: 534K
Today's EPS Names:
ATU, CRWS, CLC, More
Trade AMRI Now!
Albany Molecular Research (NASDAQ: AMRI) reported Q2 EPS of $0.06, $0.04 better than the analyst estimate of $0.02. Revenue for the quarter came in at $50 million versus the consensus estimate of $52 million.
Guides Q312 contract revenue to range from $43 million to $46 million. Affirms FY12 contract revs outlook.
For earnings history and earnings-related data on Albany Molecular Research (AMRI) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Guides Q312 contract revenue to range from $43 million to $46 million. Affirms FY12 contract revs outlook.
For earnings history and earnings-related data on Albany Molecular Research (AMRI) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Actuant Corp. (ATU) Tops Q3 EPS by 3c; Trims FY13 Outlook, Guides FY14
- John Wiley (JW-A) Misses Q4 EPS by 9c; Names New CFO; Updates on Restructuring
- AMRI Burlington Receives DEA Approval to Handle Controlled Substances
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
